CoLucid Pharmaceuticals, Inc. 4
4 · CoLucid Pharmaceuticals, Inc. · Filed Dec 5, 2016
Insider Transaction Report
Form 4
Mathers Thomas P.
DirectorChief Executive Officer
Transactions
- Exercise/Conversion
Common Stock
2016-12-05+3,756→ 255,768 total - Sale
Common Stock
2016-12-05$38.75/sh−1,502$58,203→ 254,266 total - Exercise/Conversion
Restricted Stock Units
2016-12-05−3,756→ 108,902 total→ Common Stock (3,756 underlying)
Footnotes (4)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of CoLucid Pharmaceuticals, Inc. common stock.
- [F2]Includes 3,092 shares acquired under the CoLucid Pharmaceuticals, Inc. Employee Stock Purchase Plan through November 30, 2016.
- [F3]Securities sold pursuant to a written plan intended to comply with Rule 10b5-1(c)(i) adopted by Mr. Mathers on August 19, 2016. The purpose of the plan was to sell shares of common stock in order to pay the taxes related to the settlement of the RSUs.
- [F4]On May 5, 2015, the reporting person received 360,508 RSUs. Those RSUs vest as follows: 50% of the RSUs vested on November 5, 2015; 12.5% of the RSUs vested on May 5, 2016; and the remaining RSUs vest in a series of 36 successive equal monthly installments upon completion of each additional month of service.